Owens David 4
4 · Nexalin Technology, Inc. · Filed Feb 27, 2025
Insider Transaction Report
Form 4
Owens David
DirectorChief Medical Officer
Transactions
- Award
Stock Option (right to buy)
2025-02-26+654,363→ 794,184 totalExercise: $0.89Exp: 2034-06-30→ Common Stock (654,363 underlying) - Award
Stock Option (right to buy)
2025-02-26+139,821→ 139,821 totalExercise: $0.89From: 2025-02-26Exp: 2033-06-30→ Common Stock (139,821 underlying) - Award
Stock Option (right to buy)
2025-02-26+125,000→ 919,184 totalExercise: $2.95From: 2025-02-26Exp: 2029-12-27→ Common Stock (125,000 underlying)
Footnotes (1)
- [F1]The option vests in three equal annual installments based on the satisfaction of certain performance criteria for each of the annual periods ending June 30, 2024, 2025 and 2026. The performance criteria for the period ending June 30, 2024 were met, resulting in the vesting of options to purchase 218,121 shares.